Related Experiment Video
Updated: Feb 12, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy
Constantinos O'Mahony1, Saidi A Mohiddin1, Charles Knight1
1The Heart Muscle Disease Clinic, London Chest Hospital, London, UK.
Insights
Hypertrophic cardiomyopathy (HCM) can cause obstructive symptoms. For drug-refractory cases, alcohol septal ablation (ASA) is a key treatment option to consider for left ventricular outflow tract obstruction (LVOTO).
Area of Science:
- Cardiology
- Inherited Cardiovascular Diseases
Background:
- Hypertrophic cardiomyopathy (HCM) is an inherited heart muscle disease.
- A subset of HCM patients experience left ventricular outflow tract obstruction (LVOTO), leading to severe symptoms.
- Current guidelines suggest medical management for symptomatic HCM, escalating to invasive options if refractory.
Purpose of the Study:
- To provide an overview of HCM and LVOTO pathophysiology.
- To review the role and efficacy of alcohol septal ablation (ASA) in managing drug-refractory LVOTO in HCM patients.
Main Methods:
- Literature review focusing on HCM, LVOTO mechanisms, and treatment modalities.
- Analysis of the application and outcomes of ASA in the context of drug-refractory LVOTO.
Main Results:
- HCM is characterized by left ventricular hypertrophy.
- LVOTO can significantly limit patient function and quality of life.
- ASA presents a viable therapeutic option for carefully selected patients with drug-refractory LVOTO.
Conclusions:
- Effective management of symptomatic LVOTO in HCM is crucial.
- Multidisciplinary evaluation is essential for treatment decisions.
- Alcohol septal ablation (ASA) is an important interventional tool for drug-refractory obstructive hypertrophic cardiomyopathy.
Abstract:
Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disorder characterised by left ventricular hypertrophy. A subgroup of patients develops limiting symptoms in association with left ventricular outflow tract obstruction (LVOTO). Current international guidelines recommend that symptomatic patients are initially treated by alleviating exacerbating factors and negatively inotropic medication. Drug-refractory symptoms require a comprehensive evaluation of the mechanism of LVOTO and review by a multidisciplinary team to consider the relative merits of myectomy, alcohol septal ablation (ASA) and pacing. This article provides a brief overview of HCM and the pathophysiology of LVOTO, and reviews the use of ASA in patients with drug-refractory symptoms secondary to LVOTO.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management

